Duncker Streett & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-66
| Closed | -$2.7K | – | 541 |
|
|
2024
Q3 | $2.7K | Buy |
+66
| New | +$2.7K | ﹤0.01% | 443 |
|
|
2020
Q4 | – | Sell |
-1,634
| Closed | -$77K | – | 532 |
|
|
2020
Q3 | $77K | Hold |
1,634
| – | – | 0.02% | 293 |
|
|
2020
Q2 | $83K | Sell |
1,634
-496
| -23% | -$25.4K | 0.02% | 289 |
|
|
2020
Q1 | $101K | Hold |
2,130
| – | – | 0.03% | 270 |
|
|
2019
Q4 | $125K | Buy |
+2,130
| New | +$118K | 0.03% | 279 |
|
|
2019
Q3 | – | Sell |
-2,121
| Closed | -$106K | – | 346 |
|
|
2019
Q2 | $106K | Buy |
2,121
+7
| +0.3% | +$351 | 0.02% | 301 |
|
|
2019
Q1 | $110K | Buy |
2,114
+5
| +0.2% | +$250 | 0.03% | 298 |
|
|
2018
Q4 | $101K | Sell |
2,109
-234
| -10% | -$11.5K | 0.03% | 286 |
|
|
2018
Q3 | $118K | Buy |
2,343
+5
| +0.2% | +$254 | 0.03% | 303 |
|
|
2018
Q2 | $118K | Buy |
2,338
+6
| +0.3% | +$302 | 0.03% | 294 |
|
|
2018
Q1 | $114K | Buy |
2,332
+6
| +0.3% | +$279 | 0.03% | 299 |
|
|
2017
Q4 | $103K | Buy |
2,326
+5
| +0.2% | +$231 | 0.03% | 320 |
|
|
2017
Q3 | $118K | Buy |
2,321
+4
| +0.2% | +$203 | 0.04% | 293 |
|
|
2017
Q2 | $125K | Buy |
2,317
+6
| +0.3% | +$320 | 0.04% | 285 |
|
|
2017
Q1 | $122K | Buy |
2,311
+5
| +0.2% | +$254 | 0.04% | 291 |
|
|
2016
Q4 | $111K | Buy |
2,306
+4
| +0.2% | +$198 | 0.04% | 295 |
|
|
2016
Q3 | $124K | Buy |
2,302
+4
| +0.2% | +$219 | 0.04% | 268 |
|
|
2016
Q2 | $125K | Buy |
2,298
+5
| +0.2% | +$263 | 0.04% | 265 |
|
|
2016
Q1 | $116K | Buy |
2,293
+373
| +19% | +$18.6K | 0.04% | 267 |
|
|
2015
Q4 | $97K | Hold |
1,920
| – | – | 0.04% | 291 |
|
|
2015
Q3 | $92K | Hold |
1,920
| – | – | 0.04% | 301 |
|
|
2015
Q2 | $100K | Hold |
1,920
| – | – | 0.03% | 304 |
|
|
2015
Q1 | $111K | Hold |
1,920
| – | – | 0.04% | 293 |
|
|
2014
Q4 | $103K | Sell |
1,920
-80
| -4% | -$4.48K | 0.03% | 304 |
|
|
2014
Q3 | $115K | Buy |
2,000
+160
| +9% | +$9.81K | 0.04% | 299 |
|
|
2014
Q2 | $123K | Buy |
1,840
+560
| +44% | +$37.9K | 0.04% | 309 |
|
|
2014
Q1 | $85K | Hold |
1,280
| – | – | 0.03% | 323 |
|
|
2013
Q4 | $85K | Hold |
1,280
| – | – | 0.03% | 316 |
|
|
2013
Q3 | $80K | Hold |
1,280
| – | – | 0.03% | 303 |
|
|
2013
Q2 | $80K | Buy |
+1,280
| New | +$81.2K | 0.03% | 312 |
|
Other funds holding GSK
JEST
Duncker Streett & Co's GSK Position: Q4 2024 in Review
Duncker Streett & Co sold out of GSK (GSK) in Q4 2024, closing a stake of 66 shares — an estimated $2.7K sold.
Duncker Streett & Co first reported a position in GSK in Q2 2013 and held it in 30 quarters. The position peaked at $125K in Q4 2019. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.
- Duncker Streett & Co reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
- Duncker Streett & Co sold 66 GSK shares in Q4 2024, an estimated $2.7K.
- Duncker Streett & Co first reported a position in GSK in Q2 2013 and held it in 30 quarters.
- Duncker Streett & Co's GSK position peaked at $125K in Q4 2019.
- 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.
Based on Duncker Streett & Co's 13F filing for Q4 2024, filed 5 Feb 2025.